Načítá se...
Metabolic Targets in Nonalcoholic Fatty Liver Disease
The prevalence and diagnosis of nonalcoholic fatty liver disease (NAFLD) is on the rise worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease burden of NAFLD and a more severe form of this progressive liver disease, nonalcoholic steatohepatitis (NASH), largely mirrors...
Uloženo v:
| Vydáno v: | Cell Mol Gastroenterol Hepatol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6698700/ https://ncbi.nlm.nih.gov/pubmed/31004828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcmgh.2019.04.007 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|